Canada Markets open in 9 hrs 25 mins
  • S&P/TSX

    20,985.37
    +57.27 (+0.27%)
     
  • S&P 500

    4,486.46
    +15.09 (+0.34%)
     
  • DOW

    35,258.61
    -36.15 (-0.10%)
     
  • CAD/USD

    0.8100
    +0.0020 (+0.2487%)
     
  • BTC-CAD

    77,331.38
    +213.66 (+0.28%)
     
  • CMC Crypto 200

    1,465.36
    +13.73 (+0.95%)
     
  • GOLD FUTURES

    1,775.00
    +9.30 (+0.53%)
     
  • RUSSELL 2000

    2,267.84
    +2.19 (+0.10%)
     
  • 10-Yr Bond

    1.5840
    +0.0650 (+4.28%)
     
  • VOLATILITY

    16.31
    +0.01 (+0.06%)
     
  • FTSE

    7,203.83
    -30.20 (-0.42%)
     
  • NIKKEI 225

    29,246.03
    +220.57 (+0.76%)
     
  • CAD/EUR

    0.6952
    -0.0003 (-0.04%)
     

Those who invested in Surgery Partners (NASDAQ:SGRY) three years ago are up 219%

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Surgery Partners, Inc. (NASDAQ:SGRY) shareholders might be concerned after seeing the share price drop 25% in the last quarter. But in three years the returns have been great. Indeed, the share price is up a very strong 219% in that time. It's not uncommon to see a share price retrace a bit, after a big gain. If the business can perform well for years to come, then the recent drop could be an opportunity.

Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.

View our latest analysis for Surgery Partners

Surgery Partners isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In the last 3 years Surgery Partners saw its revenue grow at 5.5% per year. That's not a very high growth rate considering it doesn't make profits. In comparison, the share price rise of 47% per year over the last three years is pretty impressive. We'd need to take a closer look at the revenue and profit trends to see whether the improvements might justify that sort of increase. It may be that the market is pretty optimistic about Surgery Partners if you look to the bottom line.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

A Different Perspective

It's nice to see that Surgery Partners shareholders have received a total shareholder return of 141% over the last year. That's better than the annualised return of 22% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. It's always interesting to track share price performance over the longer term. But to understand Surgery Partners better, we need to consider many other factors. Even so, be aware that Surgery Partners is showing 4 warning signs in our investment analysis , and 1 of those makes us a bit uncomfortable...

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting